Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

Everolimus 2Sirolimus 1Medical Marijuana 1Immunoglobulins, Intravenous 1Aspirin 1Anticonvulsants 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Epilepsy × Everolimus × Clear all
NCT02451696 2021-09-01

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

NYU Langone Health

Phase 2 Completed
15 enrolled 9 charts

Focal Cortical Dysplasia, Epilepsy, Tuberous Sclerosis

NCT01997255 2016-05-05

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Baylor College of Medicine

Phase 2 Withdrawn

Epilepsy, Glaucoma, Sturge-Weber Syndrome, Port-Wine Stain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡